Skip to content
Subscriber Only

Retrophin Sues Founder in Latest Fight Over Use of Funds

Updated on

Retrophin Inc. sued its founder Martin Shkreli for $65 million, claiming he breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds.

Shkreli left the company, which develops treatments for diseases including muscular dystrophy, in September 2014. He’s been the target of investor lawsuits over his trading in Retrophin stock, and the company has said it received a subpoena tied to a probe by federal prosecutors in Brooklyn, New York. The government requested information on Shkreli, Retrophin said.